Open AccessA Nationwide Study on the Incidence of Breast Cancer in Korean Women with Osteoporosis Receiving Raloxifene Treatment
Author(s) -
Jihyoun Lee,
Ji Sung Lee,
Jong Eun Lee,
Zisun Kim,
Sun Wook Han,
Sung Mo Hur,
Young Jin Choi,
Sung Min Park
Publication year - 2021
Publication title -
journal of breast cancer/journal of breast cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1
H-Index - 36
eISSN - 2092-9900
pISSN - 1738-6756
DOI - 10.4048/jbc.2021.24.e28
Subject(s) - raloxifene , medicine , breast cancer , osteoporosis , incidence (geometry) , oncology , gynecology , cancer , tamoxifen , physics , optics
Raloxifene is a selective estrogen receptor modulator (SERM), and raloxifene treatment for osteoporosis is reimbursable under the Korean National Health Insurance. Evidence suggests that SERMs use reduces the risk of breast cancer in Asian population. Herein, we retrospectively investigated the protective effect of raloxifene on breast cancer rates in Korean population.